Covered recipient · General Payments record
MICHAEL G KNIGHT
Allopathic & Osteopathic Physicians Internal Medicine
General Payments · PY2018–2024
$113,698.56
- Reported across 90 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $34,799.75 | 10 |
| Travel and Lodging | $5,388.91 | 12 |
| Food and Beverage | $1,474.65 | 6 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Novo Nordisk AS | $35,036.23 | 20 |
| Gilead Sciences, Inc. | $5,085.67 | 6 |
| Novo Nordisk AS | $1,500.00 | 1 |
| Currax Pharmaceuticals LLC | $41.41 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (28)
Sorted by paying entity, then date · as published by CMS
Program year 2024 201820192020202120222023
Record-level detail is published for PY2024; earlier years are summarised in
“By program year”.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Currax Pharmaceuticals LLC | $41.41 | 11/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1089513494 | CMS |
| Gilead Sciences, Inc. | $16.55 | 08/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133756551 | CMS |
| Gilead Sciences, Inc. | $248.48 | 08/05/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1133863010 | CMS |
| Gilead Sciences, Inc. | $4,280.00 | 08/15/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1133598901 | CMS |
| Gilead Sciences, Inc. | $38.21 | 08/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133756553 | CMS |
| Gilead Sciences, Inc. | $190.26 | 08/22/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1133863012 | CMS |
| Gilead Sciences, Inc. | $312.17 | 08/22/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1133863014 | CMS |
| Novo Nordisk AS | $1,500.00 | 10/21/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1096551987 | CMS |
| Novo Nordisk Inc | $3,879.00 | 05/07/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1097497284 | CMS |
| Novo Nordisk Inc | $8,078.25 | 05/08/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1096663487 | CMS |
| Novo Nordisk Inc | $364.97 | 05/08/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1096857275 | CMS |
| Novo Nordisk Inc | $483.99 | 05/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096988609 | CMS |
| Novo Nordisk Inc | $967.82 | 05/08/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1097495164 | CMS |
| Novo Nordisk Inc | $872.60 | 05/08/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1097693504 | CMS |
| Novo Nordisk Inc | $750.00 | 09/03/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1096583611 | CMS |
| Novo Nordisk Inc | $750.00 | 09/03/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1097089898 | CMS |
| Novo Nordisk Inc | $562.50 | 09/24/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1097492477 | CMS |
| Novo Nordisk Inc | $6,843.75 | 09/25/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1096861562 | CMS |
| Novo Nordisk Inc | $202.07 | 09/25/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1096906573 | CMS |
| Novo Nordisk Inc | $592.28 | 09/25/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1096915450 | CMS |
| Novo Nordisk Inc | $511.21 | 09/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097495514 | CMS |
| Novo Nordisk Inc | $391.50 | 09/25/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1097499410 | CMS |
| Novo Nordisk Inc | $1,125.00 | 11/12/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1097009985 | CMS |
| Novo Nordisk Inc | $7,031.25 | 11/13/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1096887012 | CMS |
| Novo Nordisk Inc | $653.14 | 11/13/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1097086637 | CMS |
| Novo Nordisk Inc | $470.50 | 11/13/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1097492721 | CMS |
| Novo Nordisk Inc | $123.12 | 11/13/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1097693589 | CMS |
| Novo Nordisk Inc | $383.28 | 11/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097838561 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.